Identification of Genes and Pathways Involved in Malignant Pleural Mesothelioma Using Bioinformatics Methods

Overview

Journal BMC Med Genomics

Publisher Biomed Central

Specialty Genetics

Date 2021 Apr 14

PMID 33849532

Citations 5

Authors

Xingsheng Liu

Kun Qian

Gaojun Lu

Peng Chen

Yi Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Malignant pleural mesothelioma (MPM) is a rare tumor in the pleura. This study was carried out to identify key genes and pathways that may be involved in MPM.

Methods: Microarray datasets GSE51024 and GSE2549 were analyzed for differentially expressed genes (DEGs) between normal and MPM tissues. The identified DEGs were subjected to functional analyses using bioinformatics tools.

Results: A total of 276 DEGs were identified, consisting of 187 downregulated and 79 upregulated genes. Gene ontology and Kyoto encyclopedia of genes and genomes pathway enrichment analysis indicated that the DEGs were enriched in extracellular structure organization, extracellular matrix, and ECM-receptor interaction. Due to high degree of connectivity among 24 hub genes, EZH2 and HMMR are likely to play roles in the carcinogenesis and progression of MPM. The two genes were found over-expressed in MPM tissues. Patients with elevated EZH2 and HMMR expressions had poor overall survival.

Conclusions: EZH2 and HMMR are identified to be the hub genes for MPM and they may be further characterized to better understand the molecular mechanisms underlying the carcinogenesis of MPM.

Citing Articles

Comprehensive Analysis Identifies Hyaluronan Mediated Motility Receptor and Cell Division Cycle 25C as Potential Prognostic Biomarkers in Head and Neck Squamous Cell Carcinoma.

Zhang H, Xu Y, Han H, Ye X, Cheng L, Shen Y Cancer Control. 2024; 31:10732748241287904.

PMID: 39323031 PMC: 11440566. DOI: 10.1177/10732748241287904.

Benefits and Challenges of Inhibiting EZH2 in Malignant Pleural Mesothelioma.

Al Khatib M, Pinton G, Moro L, Porta C Cancers (Basel). 2023; 15(5).

PMID: 36900330 PMC: 10000483. DOI: 10.3390/cancers15051537.

Advances in Immunotherapy of Malignant Pleural Mesothelioma.

Liao D, Yu Y, Mei Q, Wang Z, Li X, Jia Y Onco Targets Ther. 2021; 14:4477-4484.

PMID: 34429612 PMC: 8374846. DOI: 10.2147/OTT.S317434.

A network-biology approach for identification of key genes and pathways involved in malignant peritoneal mesothelioma.

Mahfuz A, Zubair-Bin-Mahfuj A, Podder D Genomics Inform. 2021; 19(2):e16.

PMID: 34261301 PMC: 8261271. DOI: 10.5808/gi.21019.

Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma.

Napoli F, Listi A, Zambelli V, Witel G, Bironzo P, Papotti M Cancers (Basel). 2021; 13(11).

PMID: 34073720 PMC: 8197227. DOI: 10.3390/cancers13112564.

References

LaFave L, Beguelin W, Koche R, Teater M, Spitzer B, Chramiec A . Loss of BAP1 function leads to EZH2-dependent transformation. Nat Med. 2015; 21(11):1344-9. PMC: 4636469. DOI: 10.1038/nm.3947. View

Kaarteenaho-Wiik R, Soini Y, Pollanen R, Paakko P, Kinnula V . Over-expression of tenascin-C in malignant pleural mesothelioma. Histopathology. 2003; 42(3):280-91. DOI: 10.1046/j.1365-2559.2003.01568.x. View

Suveg K, Putora P, Berghmans T, Glatzer M, Kovac V, Cihoric N . Current efforts in research of pleural mesothelioma-An analysis of the ClinicalTrials.gov registry. Lung Cancer. 2018; 124:12-18. DOI: 10.1016/j.lungcan.2018.07.007. View

Leong S, Zainudin R, Kazan-Allen L, Robinson B . Asbestos in Asia. Respirology. 2015; 20(4):548-55. DOI: 10.1111/resp.12517. View

Bueno R, Stawiski E, Goldstein L, Durinck S, De Rienzo A, Modrusan Z . Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016; 48(4):407-16. DOI: 10.1038/ng.3520. View

Chandrashekar D, Bashel B, Balasubramanya S, Creighton C, Ponce-Rodriguez I, Chakravarthi B . UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017; 19(8):649-658. PMC: 5516091. DOI: 10.1016/j.neo.2017.05.002. View

Suraokar M, Nunez M, Diao L, Chow C, Kim D, Behrens C . Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications. Ann Oncol. 2014; 25(6):1184-92. PMC: 4037861. DOI: 10.1093/annonc/mdu127. View

Gango A, Batai B, Varga M, Kapczar D, Papp G, Marschalko M . Concomitant 1p36 deletion and TNFRSF14 mutations in primary cutaneous follicle center lymphoma frequently expressing high levels of EZH2 protein. Virchows Arch. 2018; 473(4):453-462. DOI: 10.1007/s00428-018-2384-3. View

Hylebos M, Van Camp G, van Meerbeeck J, Op de Beeck K . The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing. J Thorac Oncol. 2016; 11(10):1615-26. DOI: 10.1016/j.jtho.2016.05.020. View

10.

Griffiths S, Loveday C, Zachariou A, Behan L, Chandler K, Cole T . EED and EZH2 constitutive variants: A study to expand the Cohen-Gibson syndrome phenotype and contrast it with Weaver syndrome. Am J Med Genet A. 2019; 179(4):588-594. DOI: 10.1002/ajmg.a.61066. View

11.

Kemp C, Rao M, Xi S, Inchauste S, Mani H, Fetsch P . Polycomb repressor complex-2 is a novel target for mesothelioma therapy. Clin Cancer Res. 2011; 18(1):77-90. PMC: 6310139. DOI: 10.1158/1078-0432.CCR-11-0962. View

12.

Irizarry R, Bolstad B, Collin F, Cope L, Hobbs B, Speed T . Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003; 31(4):e15. PMC: 150247. DOI: 10.1093/nar/gng015. View

13.

Ernst A, Schlattmann P, Waldfahrer F, Westhofen M . . Laryngorhinootologie. 2017; 96(8):519-521. DOI: 10.1055/s-0043-113690. View

14.

Remon J, Lianes P, Martinez S, Velasco M, Querol R, Zanui M . Malignant mesothelioma: new insights into a rare disease. Cancer Treat Rev. 2013; 39(6):584-91. DOI: 10.1016/j.ctrv.2012.12.005. View

15.

Rhodes D, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs B . Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007; 9(2):166-80. PMC: 1813932. DOI: 10.1593/neo.07112. View

16.

Gemignani F, Neri M, Bottari F, Barale R, Canessa P, Canzian F . Risk of malignant pleural mesothelioma and polymorphisms in genes involved in the genome stability and xenobiotics metabolism. Mutat Res. 2009; 671(1-2):76-83. DOI: 10.1016/j.mrfmmm.2009.09.003. View

17.

Bahrami S, Tolg C, Peart T, Symonette C, Veiseh M, Umoh J . Receptor for hyaluronan mediated motility (RHAMM/HMMR) is a novel target for promoting subcutaneous adipogenesis. Integr Biol (Camb). 2017; 9(3):223-237. PMC: 5476222. DOI: 10.1039/c7ib00002b. View

18.

Cedres S, Montero M, Martinez P, Martinez A, Rodriguez-Freixinos V, Torrejon D . Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). Lung Cancer. 2012; 77(1):192-8. DOI: 10.1016/j.lungcan.2012.02.022. View

19.

Ou S, Moon J, Garland L, Mack P, Testa J, Tsao A . SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol. 2015; 10(2):387-91. PMC: 4304604. DOI: 10.1097/JTO.0000000000000360. View

20.

Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M . KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 2015; 44(D1):D457-62. PMC: 4702792. DOI: 10.1093/nar/gkv1070. View